Skip to main content

Diabeloop’s Automated Insulin Delivery System to Launch In Europe

Updated: 8/14/21 2:00 amPublished: 12/13/18
By Adam BrownJeemin Kwon

By Jeemin Kwon, Brian Levine, and Adam Brown

Diabeloop’s automated insulin delivery system includes the Kaleido insulin pump, an Android controller, and the Dexcom G6 CGM; it is the second hybrid closed loop approved in Europe for adults with type 1 diabetes

Diabeloop’s hybrid closed loop system, called ‘DBLG1,’ has received a CE mark – this means that the company can now launch the automated insulin delivery (AID) system in Europe. DBLG1 will first launch in France in early 2019, followed by other European countries. For adults with type 1 diabetes, this is the second AID system to be approved in Europe, in addition to the Medtronic MiniMed 670G. Getting on a hybrid closed loop system – which automates basal insulin delivery based on CGM readings – translates to more time-in-range (70-180 mg/dl), a lower average blood sugar, less ups and downs, and better sleep. For background on AID systems, click here.

At launch, the DBLG1 system will include a Kaleido insulin pump worn on the body, the Dexcom G6 CGM, and Diabeloop’s own locked-down touchscreen controller (no cellular or app capabilities). The controller will receive Dexcom CGM readings and trends, run them through an algorithm, and then tell the pump to adjust basal insulin accordingly. Since the Diabeloop algorithm is contained in the controller, the handheld must be in range to remain in closed loop; if it’s out of range for more than 25 minutes, the pump reverts back to a reference basal rate. Additional notable features include:

  • Users can adjust the algorithm target between 100 – 130 mg/dl

  • A ‘Zen mode’ virtually ensures no lows over a short time period

  • Option to share and analyze data, potentially with a healthcare provider

A 12-week study presented at ADA showed that compared to regular pump therapy with a CGM, Diabeloop’s system users saw a:

  • Two hour increase in time-in-range (70-180 mg/dl) per day – 69% with closed loop vs. 57% on open loop.

  • 50 fewer minutes per day spent in hypoglycemia (below 70 mg/dl) – 1.6% with closed loop vs. 4.9% on open loop.

  • Notably, roughly 75% of DBLG1 users stop counting carbs with the system. We’re not positive, but we’d guess this means users tell the system “I’m about to eat” – and perhaps if the meal is small, medium or large – but they don’t need to enter a specific number of carbs. From there, the system makes decisions about insulin based on CGM trends.

Pricing information has not yet been shared.

The system is currently compatible with the Kaleido pump, and the company is also working to integrate Cellnovo’s pump. Both pumps are worn directly on the body like a patch, but include a short infusion set (see picture). Currently, the Kaleido pump is only available in the Netherlands and has just launched. We do like the slim on-body design and friendly color!

What do you think?

About the authors

Adam Brown joined diaTribe in 2010 as a Summer Associate, became Managing Editor in 2011, and served as Senior Editor through 2019. Adam brings almost two decades of personal experience... Read the full bio »